TAIPEI, TAIWAN - Media OutReach Newswire - 12 June 2026 - TVBS deployed its self-developed real-time AI translation system during NVIDIA CEO Jensen Huang's keynote at GTC Taipei 2026 on June 1. The system delivered near-simultaneous Chinese subtitles that viewers initially mistook for official NVIDIA translations. The in-house technology marked a rare instance of a news organization independently developing live translation for a large-scale broadcast.
TVBS deployed its self-developed real-time AI translation system during NVIDIA CEO Jensen Huang's keynote at GTC Taipei 2026 on June 1.
Online viewers praised the translation quality, with comments including "The quality of this real-time translation is amazing," "The translation is incredibly fast," and "The live speech recognition quality is surprisingly good." Some viewers assumed the subtitles came from NVIDIA's official translation team.
The achievement demonstrates how Taiwan's media industry is adapting to AI-driven transformation. TVBS is positioning itself as a leader in integrating proprietary AI development with real-world broadcast applications. The company completed optimization and deployment of the system in just nine days — a process that traditionally requires months of dedicated training, according to Andy Yang, manager of TVBS AI Future Technology Department.
Yang explained that the biggest challenge in real-time translation lies in balancing "content accuracy" with "reading fluency" under extremely tight time constraints. Huang's speaking style is highly improvisational and frequently switches between English, Mandarin and Taiwanese, while audience applause and cheering often occur simultaneously.
Applying standard off-the-shelf translation software in such an environment would likely result in sentence segmentation errors and unclear semantic interpretation, Yang said. Rather than pursuing "zero-latency" translation at all costs, TVBS designed a subtitle presentation mechanism specifically tailored to the keynote format.
Prior to the event, the TVBS team conducted extensive cross-platform testing on multiple AI translation models, evaluating latency and error rates. By introducing a carefully calibrated broadcast delay, the system gained additional time to process semantic meaning and contextual alignment. This approach enabled smoother subtitles matching natural Chinese reading habits, Yang said.
The team also built a dedicated knowledge base for NVIDIA GTC Taipei, compiling AI industry terminology, product names and technical keywords in advance. This significantly improved translation quality and the accuracy of professional content delivery. TVBS's real-time translation system can be customized based on different broadcasting scenarios, Yang noted.
Yang emphasized that the key to the rapid nine-day deployment was cross-department collaboration. Engineering teams handled hardware tuning and signal integration, while internal technical and content teams managed ongoing model training and refinement. TVBS established a collaborative workflow integrating both technology and editorial expertise.
Through continuous iteration and adjustment, the team incorporated Taiwanese linguistic nuances and natural Chinese phrasing into the system. This enhanced fluency and readability beyond what generic AI models alone could achieve, ultimately shaping what Yang called a distinct "TVBS AI style." The approach reflects the company's "3T" philosophy — Truth, Trust and Technology.
In his keynote at the Taipei Music Center, Huang focused on AI infrastructure, next-generation computing platforms and NVIDIA's latest technological roadmap. GTC Taipei 2026 attracted significant international attention as AI continues to reshape global industries. Through its own transformation journey, TVBS hopes to help lead Taiwan's media industry into a new era shaped by AI.
Hashtag: #TVBS
The issuer is solely responsible for the content of this announcement.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
Nationwide #AreYourKidneysOK+? initiative expands access to subsidised blood screening, public education, and pharmacist support for 12,550 Malaysians.
KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 19 August 2026 – As chronic conditions such as diabetes, cardiovascular disease and chronic kidney disease continue to affect Malaysians, early detection is becoming increasingly important in reducing complications and improving long-term health outcomes.
(From left: Dr. Cheng Yong Fatt (Consultant Nephrologist of KPJ Seremban Specialist Hospital); Dr. Svetlana Yanchuk (Country President of AstraZeneca Malaysia); Ph. Hiew Fei Tsong (Co-founder of Alpro Group); Dr. Ng Ming Lee (Medical Director of Alpro Clinic); Ms Jenny Poon (Business Unit Director of CVRM/R&I of AstraZeneca Malaysia); Dr. Yong Lit Sin (Consultant Endocrinologist of Columbia Asia Hospital Seremban)
These conditions are closely interconnected across the Cardio-Kidney-Metabolic spectrum, meaning that a problem affecting one area of health may also increase the risks to other parts of the body. However, many individuals may not recognise these risks until their condition has progressed or complications have developed.
One such complication is hyperkalemia, a condition characterised by elevated potassium levels in the blood. Hyperkalemia is more common among people living with chronic kidney disease because impaired kidneys may have lower ability to remove excess potassium from the body. As the condition may not always present noticeable warning signs, it remains under-recognised by the public and may lead to serious complications affecting the heart's rhythm if not appropriately identified and managed.
Recognising the need to strengthen early detection and public awareness across the Cardio-Kidney-Metabolic (CKM) spectrum, Alpro Group, in collaboration with AstraZeneca Malaysia, announced the launch of #AreYourKidneysOK+?, a nationwide awareness campaign dedicated to encourage early detection, promoting kidney health, and raising awareness of hyperkalemia.
This nationwide initiative aims to empower Malaysians to better understand the connection between their heart, kidney and metabolic health, while bringing greater attention to hyperkalemia as an often-overlooked complication associated with chronic kidney disease.
At the heart of the campaign is a subsidised blood screening programme aimed at encouraging more Malaysians to take an earlier and more proactive approach to their health. Eligible individuals will receive subsidy on selected blood test packages, to reduce financial barriers in screening and to support the earlier identification of potential Cardio-Kidney-Metabolic and health risks.
The campaign aims to reach 12,550 individuals across Malaysia, a shared commitment by Alpro Group and AstraZeneca Malaysia to turn public health awareness into meaningful action.
Beyond providing financial support for screening, the campaign creates a more accessible pathway for Malaysians to learn about their potential health risks, undergo appropriate screening and speak to their healthcare professionals about the next steps they may need to undertake.
To extend the campaign's reach beyond physical pharmacy locations, the initiative is supported by a dedicated digital health education platform containing trusted and easy-to-understand information about hyperkalemia, including its causes, risk factors, possible warning signs and relationship with chronic kidney disease.
The platform serves as a public health resource that Malaysians can access at any time, helping individuals and caregivers better understand hyperkalemia and prepare for more informed conversations with pharmacists, doctors and other healthcare professionals.
Through Alpro Group's community healthcare network, members of the public will also have greater access to pharmacist support and guidance. Alpro pharmacists can help individuals better understand the importance of screening, recognise relevant risk factors and seek appropriate medical assessment or follow-up when necessary.
"Many chronic health risks develop quietly and may only be discovered after complications have occurred. Through this campaign, we want to make preventive healthcare more accessible by connecting public education, affordable screening and professional healthcare support. By targeting 12,550 Malaysians, we hope to encourage more people to take an earlier and more proactive step towards understanding their heart, kidney and metabolic health," said Dr. Ng Ming Lee, Medical Director of Alpro Clinic.
"As chronic kidney disease remains a significant public health challenge in Malaysia, this collaboration reflects a shared commitment across the healthcare ecosystem to strengthen public awareness of kidney health and bring health education closer to the public. Through Alpro Group's nationwide network, we aim to help more Malaysians learn about relevant risk factors and have informed conversations with healthcare professionals to support appropriate assessment and follow-up," said Dr. Svetlana Yanchuk, Country President, AstraZeneca Malaysia.
Through this collaboration, Alpro Group and AstraZeneca Malaysia reaffirm their shared commitment to advancing preventive healthcare by combining greater public awareness, accessible screening and professional healthcare support.
The campaign also demonstrates the important role that community pharmacies can play in supporting wider public health efforts by providing Malaysians with convenient access to health education, early screening opportunities and trusted professional guidance within their communities.
Members of the public are encouraged to learn more about hyperkalemia by visiting www.alpropharmacy.com/pages/hyperkalemia or by speaking to an Alpro pharmacist.
References
1. KDIGO Controversies Conference. Potassium Homeostasis and Management of Dyskalemia in Kidney Diseases. Kidney International (2020). [kdigo.org]
2. National Kidney Foundation. High Potassium (Hyperkalemia): Causes, Symptoms, and Treatment (updated 2025).
Hashtag: #AlproPharmacy #AlproGroup #AreYourKidneysOK+?
The issuer is solely responsible for the content of this announcement.
About Alpro Group
Founded in 2002, Alpro Group's ecosystem has grown to include Alpro Pharmacy, Apotek Alpro, Alpro スギ (Sugi) Pharmacy, Alpro Physio, Alpro Clinic, Alpro Baby, Alpro OptiSaver, Alpro Audiology, Alpro Health, and Alpro Foundation. Supported by a team of more than 1,000 healthcare professionals, including doctors, pharmacists, nutritionists, dietitians, physiotherapists, optometrist and many others, Alpro serves over 5 million families in Malaysia and Indonesia through its extensive network of 500 physical outlets.
Alpro Pharmacy is the first and only community pharmacy in the region to offer product liability insurance of MYR 1 million in Malaysia and IDR 3 billion in Indonesia, ensuring the supply of genuine medications and enhancing consumer trust.
With the vision of a healthy and vibrant world, Alpro Group aims to become the No. 1 prescription pharmacy chain in Southeast Asia.
About AstraZeneca
AstraZeneca is a global, science led biopharmaceutical company focused on the discovery, development, and commercialisation of innovative medicines that transform patient outcomes. Headquartered in Cambridge, United Kingdom, the company operates in more than 100 countries and plays a significant role in advancing modern healthcare through research driven innovation and strategic partnerships worldwide.
Guided by its purpose to push the boundaries of science to deliver life changing medicines, AstraZeneca prioritises long term investment in research and development. The company's global strategy is built on deep scientific expertise, advanced technology platforms, and precision medicine approaches, including biologics, antibody drug conjugates, and data driven drug discovery. These capabilities enable AstraZeneca to address complex diseases and unmet medical needs with increasing accuracy and effectiveness.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
